Made available in DSpace on 2010-08-23T16:00:16Z (GMT). No. of bitstreams: 2
Prenatal exposure to misoprostol.pdf: 83469 bytes, checksum: b5a75bab289a9434c882199d2912fe0f (MD5)
license.txt: 1878 bytes, checksum: 4ab65ca798f15d32db061c8ec1b00ab1 (MD5)
Previous issue date: 2000Universidade Federal do Estado do Rio de Janeiro. Hospital Universitário Gaffrée-Guinle. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil.Hospital São Paulo. São Paulo, SP, Brasil.Universidade de São Paulo. Faculdade de Medicina. Instituto da Criança. Hospital das Clínicas, São Paulo, SP, Brasil.Hospital São Paulo. São Paulo, SP, Brasil.Universidade de São Paulo. Faculdade de Medicina. Instituto da Criança. Hospital das Clínicas, São Paulo, SP, Brasil.Maternidade Estadual Menino Jesus. São Paulo, Brasil.Fundação Oswaldo Cruz. Instituto Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Fernandes Figueira. Rio de Janeiro, RJ, Brasil.Instituto Materno Infantil Pernambuco. Recife, PE Brasil.Universidade Estadual de Campinas. Campinas, SP, Brasil.Funfarme. São José do Rio Preto, SP, Brasil.Hospital for Sick Children. The Motherisk Program. Toronto, Canadá.Universidade do Rio de Janeiro. Instituto National do Câncer. Unidade de Genética. Rio de Janeiro, RJ, Brasil.Prenatal exposure to misoprostol has beenassociated with Moebius and limb defects.Vascular disruption has been proposed asthe mechanism for these teratogenic effects. The present study is a multicenter, casecontrol study that was designed to compare the frequency of prenatal misoprostol use between mothers of Brazilian children diagnosedwith vascular disruption defects andmatched control mothers of children diagnosed with other types of defects. A total of 93 cases and 279 controls were recruited in eight participating centers. Prenatal exposure was identified in 32 infants diagnosed with vascular disruption defects (34.4 percent) compared with only 12 (4.3 percent) in the control group (P menor que 0.0000001). Our data suggest thatprenatal exposure to misoprostol is associated to the occurrence of vascular disruption defects in the newborns
